Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
OtherClinical Investigations (Human)

Semi-automatic tumor delineation for evaluation of 64Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume

Esben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, Andreas Pfeifer, Peter Oturai, Seppo Wang Langer, Ulrich Knigge, Claes Nøhr Ladefoged and Andreas Kjaer
Journal of Nuclear Medicine February 2021, jnumed.120.258392; DOI: https://doi.org/10.2967/jnumed.120.258392
Esben Andreas Carlsen
1 Deptartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark; Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; ENETS Neuroendocrine Tumor Center of Excellen;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Esben Andreas Carlsen
Camilla Bardram Johnbeck
1 Deptartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark; Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; ENETS Neuroendocrine Tumor Center of Excellen;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathias Loft
1 Deptartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark; Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; ENETS Neuroendocrine Tumor Center of Excellen;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mathias Loft
Andreas Pfeifer
1 Deptartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark; Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; ENETS Neuroendocrine Tumor Center of Excellen;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Oturai
1 Deptartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark; Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; ENETS Neuroendocrine Tumor Center of Excellen;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Seppo Wang Langer
2 Deptartment of Oncology, Rigshospitalet, Denmark; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Seppo Wang Langer
Ulrich Knigge
3 Deptartments of Clinical Endocrinology and Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark; ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denmark, Denmark;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ulrich Knigge
Claes Nøhr Ladefoged
4 1Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Dept. of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Denmark 2 ENETS Neuroendocrine Tumor Center of Excellence, Rigshospitalet, Copenhagen, Denm
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andreas Kjaer
1 Deptartment of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Copenhagen, Denmark; Cluster for Molecular Imaging, Department of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark; ENETS Neuroendocrine Tumor Center of Excellen;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Andreas Kjaer
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Abstract

Patients with neuroendocrine neoplasms (NEN) have heterogeneous somatostatin receptor expression with highly differentiated lesions having higher expression. Receptor expression of the total tumor burden may be visualized by somatostatin receptor imaging, e.g. 64Cu-DOTATATE PET/CT. Assessment of maximal lesion uptake is associated with progression-free survival (PFS), but not overall survival (OS). We hypothesized that the lesion with lowest, rather than highest, 64Cu-DOTATATE uptake would be more prognostic and developed a semi-automatic method for evaluating this. Methods: Patients with NEN underwent 64Cu-DOTATATE PET/CT. A standardized semi-automatic tumor delineation method was developed and used to identify the lesion with the lowest uptake, i.e. lowest of lesion mean standardized uptake values (SUV)mean. Additionally, we assessed total tumor volume derived from the semi-automatic tumor delineation. Kaplan-Meier and Cox regression analyses were used to determine association with OS and PFS. Results: In 116 patients with NEN, median PFS (95% confidence interval) was 23 (20-31) months and median OS was 85 (68-113) months. Minimum SUVmean and total tumor volume were significantly associated with PFS and OS in univariate Cox regression analyses, while SUVmax was only significant for PFS. In multivariate Cox analyses, both minimum SUVmean and total tumor volume remained statistically significant. Minimum SUVmean and total tumor volume were then dichotomized by their median, and patients were categorized into 4 groups: High/low total tumor volume and high/low minimum SUVmean. Patients with low total tumor volume and high minimum SUVmean had a hazard ratio (95% confidence interval) of 0.32 (0.20-0.51) for PFS and 0.24 (0.13-0.43) for OS, both P<0.001 (reference: high total tumor volume and low minimum SUVmean). Conclusion: We propose a standardized semi-automatic tumor delineation method to identify the lesion with lowest 64Cu-DOTATATE uptake and total tumor volume. Assessment of lowest, rather than highest lesion uptake greatly increases prognostication by 64Cu-DOTATATE PET/CT. Combing lesion uptake and total tumor volume, we derived a novel prognostic classification of patients with NEN.

  • Image Processing
  • Neuroendocrine
  • PET
  • 64Cu-DOTATATE PET
  • Neuroendocrine neoplasms
  • minimum SUVmean
  • semi-automatic tumor delineation
  • total tumor volume
  • Copyright © 2021 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 63 (5)
Journal of Nuclear Medicine
Vol. 63, Issue 5
May 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Semi-automatic tumor delineation for evaluation of 64Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Semi-automatic tumor delineation for evaluation of 64Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume
Esben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, Andreas Pfeifer, Peter Oturai, Seppo Wang Langer, Ulrich Knigge, Claes Nøhr Ladefoged, Andreas Kjaer
Journal of Nuclear Medicine Feb 2021, jnumed.120.258392; DOI: 10.2967/jnumed.120.258392

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Semi-automatic tumor delineation for evaluation of 64Cu-DOTATATE PET/CT in patients with neuroendocrine neoplasms: prognostication based on lowest lesion uptake and total tumor volume
Esben Andreas Carlsen, Camilla Bardram Johnbeck, Mathias Loft, Andreas Pfeifer, Peter Oturai, Seppo Wang Langer, Ulrich Knigge, Claes Nøhr Ladefoged, Andreas Kjaer
Journal of Nuclear Medicine Feb 2021, jnumed.120.258392; DOI: 10.2967/jnumed.120.258392
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Clinical Investigations (Human)

  • Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions
  • First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic
  • Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma – the HEPAR Primary study
Show more Clinical Investigations (Human)

Clinical (Oncology: Endocrine/Neuroendocrine)

  • Repetitive early FAPI-PET acquisition comparing FAPI-02, FAPI-46 and FAPI-74: methodological and diagnostic implications for malignant, inflammatory and degenerative lesions
  • First-in-Human PET Imaging of Tissue Factor in Patients with Primary and Metastatic Cancers Using 18F-labeled Active-Site Inhibited Factor VII (18F-ASIS): Potential as Companion Diagnostic
  • Safety and efficacy of holmium-166 radioembolization in hepatocellular carcinoma – the HEPAR Primary study
Show more Clinical (Oncology: Endocrine/Neuroendocrine)

Similar Articles

Keywords

  • Image Processing
  • Neuroendocrine
  • PET
  • 64Cu-DOTATATE PET
  • neuroendocrine neoplasms
  • minimum SUVmean
  • semi-automatic tumor delineation
  • total tumor volume
SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire